webnovel

Building a Business Empire with my Technological System

Michael Reyes is your typical college student, caught in the relentless cycle of balancing studies and part-time work. As a second-year mechanical engineering student, his days are packed from dawn till dusk. Mornings are dedicated to lectures and coursework, while afternoons are spent at a part-time job that helps him make ends meet. Evenings are his only respite, though often spent more on studying than sleeping, if he gets the chance to rest at all. His life is a constant juggle, trying to keep up with demanding academic requirements while also contributing financially to his household. He's a hardworking, average student – not the top of his class, but not at the bottom either. But Michael's life takes an unexpected turn when he gains access to a mysterious Technological System. This system offers him a glimpse into future technologies, granting him knowledge and tools far beyond his time. When he realized its potential, his first words are. "I'm going to be rich!" Follow as Michael build his own business empire rivaling Apple, Microsoft, even Google. Disclaimer: 'Building a Business Empire with my Technological System' is a work of fiction. Names, characters, businesses, places, events, locales, and incidents are either the products of the author's imagination or used in a fictitious manner. Any resemblance to actual persons, living or dead, or actual events is purely coincidental. This book may reference real companies and organizations, but these references are for narrative purposes only and are not intended to depict actual conduct or involvement of these entities. The use of these names and references is not meant to harm, defame, or discredit these companies or organizations.

Faux1231 · Ficção Científica
Classificações insuficientes
400 Chs

The Decision

The board of directors, investors, and Michael exchanged an intense debate over the proposed acquisition by Aegis Pharmaceuticals. The conference room was charged with differing opinions, as some board members pointed out the immediate financial gain from the sale, while others raised concerns about the long-term impact on the company's innovations and independence. 

"I think we shouldn't sell," one board member, Thomas, said firmly. "The potential for growth in our R&D is too great to give up now. We're on the cusp of breakthroughs that could redefine entire sectors of the medical industry."

On the other side of the argument, another board member, Linda, countered, "But you're not looking at the financial security this deal offers. Two hundred billion is not just a drop in the bucket. It secures our financial future and provides capital for new ventures without the risk."